<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Influenza, an acute, highly contagious" exact="respiratory disease," post="remains a significant threat to public health. More effective"/>
 <result pre="strategies aimed at inducing broad cross-protection not only against seasonal" exact="influenza" post="variants, but also zoonotic and emerging pandemic influenza strains"/>
 <result pre="against seasonal influenza variants, but also zoonotic and emerging pandemic" exact="influenza" post="strains are urgently needed. A number of conserved protein"/>
 <result pre="the immunogenicity and efficacy of a panel of broadly protective" exact="influenza" post="vaccine prototypes based on both influenza tri-stalk and triple"/>
 <result pre="panel of broadly protective influenza vaccine prototypes based on both" exact="influenza" post="tri-stalk and triple M2e (3M2e) antigens integrated into phage"/>
 <result pre="virus challenge in mice, only the combination of both conserved" exact="influenza" post="antigens into a single VLP fully protected mice from"/>
 <result pre="single VLP fully protected mice from a high-dose homologous H1N1" exact="influenza" post="infection. We propose that a combination of genetic fusion"/>
 <result pre="fusion and chemical coupling techniques to expose two different foreign" exact="influenza" post="antigens on a single particle is a perspective approach"/>
 <result pre="broadly-effective vaccine candidate that could protect against the constantly emerging" exact="influenza" post="virus strains. influenza conserved antigens hemagglutinin stalk M2e protein"/>
 <result pre="that could protect against the constantly emerging influenza virus strains." exact="influenza" post="conserved antigens hemagglutinin stalk M2e protein virus-like particles protection"/>
 <result pre="particles protection vaccines 1. Introduction Influenza, an acute, highly contagious" exact="respiratory disease," post="remains a significant threat to public health. The co-circulating"/>
 <result pre="disease, remains a significant threat to public health. The co-circulating" exact="influenza" post="A (subtypes H1N1 and H3N2) and B (lineages Victoria"/>
 <result pre="and up to 645,832 influenza-associated deaths annually [1,2]. Consequently, seasonal" exact="influenza" post="viruses are responsible for a significant economic burden on"/>
 <result pre="burden on the health care systems and society [3,4]. Although" exact="influenza" post="is considered to be a vaccine-preventable disease, the effectiveness"/>
 <result pre="considered to be a vaccine-preventable disease, the effectiveness of seasonal" exact="influenza" post="vaccines varies greatly across the risk groups and seasons,"/>
 <result pre="effectiveness is significantly compromised by the persistent antigenic changes of" exact="influenza" post="viruses [7,8]. Continuous antibody-mediated immune pressure and the lack"/>
 <result pre="mutant variants affecting immune recognition. This process, characteristic to both" exact="influenza" post="A and B viruses, is known as antigenic drift"/>
 <result pre="outbreaks and seasonal epidemics [7,8,9,10]. Moreover, sporadic reassortment of segmented" exact="influenza" post="A virus genomes in a double-infected host cell can"/>
 <result pre="immunologically naive human population is particularly susceptible. Interspecies transmissions of" exact="influenza" post="A viruses from animal reservoirs have resulted in four"/>
 <result pre="pandemics since the beginning of the 20th century; the Spanish" exact="influenza" post="pandemic in 1918 is considered to be the most"/>
 <result pre="the vaccine effectiveness [5,6,7,8,13]. Furthermore, the components of commercially available" exact="influenza" post="vaccines are mainly obtained by propagating viruses in embryonated"/>
 <result pre="time-consuming, and expensive process with limitations for highly pathogenic avian-borne" exact="influenza" post="virus vaccine preparations [14,15]. The capability to manufacture large"/>
 <result pre="of strain-specific vaccine doses in the event of a sudden" exact="influenza" post="pandemic is limited, which means that during the months"/>
 <result pre="virus strain [11,14,15]. The persistent threat of highly pathogenic poultry" exact="influenza" post="viruses (H5Nx) and other zoonotic influenza strains (H6N1, H7N9,"/>
 <result pre="of highly pathogenic poultry influenza viruses (H5Nx) and other zoonotic" exact="influenza" post="strains (H6N1, H7N9, H10N8) overcoming the species barrier and"/>
 <result pre="[16,17,18,19]. Currently, numerous strategies to improve the effectiveness of seasonal" exact="influenza" post="vaccines, like the use of new adjuvants, increased doses,"/>
 <result pre="these approaches could not provide broad and durable protection from" exact="influenza" post="virus drift and shift variants. All these challenges indicate"/>
 <result pre="strategies aimed at inducing broad cross-protection not only against seasonal" exact="influenza" post="variants but also zoonotic and emerging pandemic influenza strains."/>
 <result pre="against seasonal influenza variants but also zoonotic and emerging pandemic" exact="influenza" post="strains. A number of conserved protein targets to elicit"/>
 <result pre="the viral envelope, these conserved antigens are immunosubdominant and natural" exact="influenza" post="infections and current vaccination regimens elicit little or no"/>
 <result pre="the highly conserved nature, vaccines based solely on one conserved" exact="influenza" post="antigen most often cannot provide complete protection against highly"/>
 <result pre="several conserved epitopes might confer broader and longer-lasting protection against" exact="influenza" post="virus infections. In the present study, we investigated the"/>
 <result pre="the immunogenicity and efficacy of a panel of broadly protective" exact="influenza" post="vaccine prototypes based on influenza HA stalk and M2e"/>
 <result pre="a panel of broadly protective influenza vaccine prototypes based on" exact="influenza" post="HA stalk and M2e antigens integrated into bacteriophage AP205"/>
 <result pre="fusion and chemical coupling techniques to expose two different foreign" exact="influenza" post="antigens on a single particle without compromising the trimeric"/>
 <result pre="broadly-effective vaccine candidate that could protect against the constantly emerging" exact="influenza" post="virus strains. Similar VLP vaccine candidates have employed a"/>
 <result pre="and M2 proteins are expressed abundantly on the surface of" exact="influenza" post="virus infected cells [37]. MDCK cell monolayers, seeded in"/>
 <result pre="In this study, to generate and test different broadly protective" exact="influenza" post="vaccine candidates, HA tri-stalk and a triple M2e protein"/>
 <result pre="platform, alone or in combination, creating five different broadly protective" exact="influenza" post="vaccine prototypes (Figure 2). Since aa 10â€&quot;24 of M2e"/>
 <result pre="(Figure 2). Since aa 10â€&quot;24 of M2e peptide vary between" exact="influenza" post="virus subtypes, combining the M2e from different subtypes can"/>
 <result pre="H1N1 and H11N9 subtypes to cover a wider range of" exact="influenza" post="viruses. Noteworthy, two of the M2e fragments comprising the"/>
 <result pre="monomeric LAH is highly immunogenic in mice when incorporated into" exact="hepatitis" post="B virus core particles [29,33]. Moreover, post-fusion LAH-specific antibodies"/>
 <result pre="bled and sera were analyzed for their reactivity to different" exact="influenza" post="antigens by ELISA. All vaccine prototypes induced high levels"/>
 <result pre="immunogens, were challenged with lethal doses of heterologous and heterosubtypic" exact="influenza" post="viruses (Figure 7). The antibody responses induced by AP-M2e"/>
 <result pre="targeted antibodies are critical for the protection against a homologous" exact="influenza" post="virus infection, and the antibodies targeted to M2e play"/>
 <result pre="group of immunized mice (Figure 12A). 4. Discussion Evolutionarily conserved" exact="influenza" post="antigens could potentially provide broad-spectrum protection against highly variable"/>
 <result pre="influenza antigens could potentially provide broad-spectrum protection against highly variable" exact="influenza" post="virus subtypes, while significantly reducing the time and costs"/>
 <result pre="vaccine production. Furthermore, recombinant vaccines help to avoid potentially harmful" exact="influenza" post="viruses grown in embryonated eggs or cell cultures and"/>
 <result pre="Here we evaluated the antigenicity and protective potential of recombinant" exact="influenza" post="vaccine prototypes, generated by combining the methods of genetic"/>
 <result pre="HA stalk as a prospective component for a broadly protective" exact="influenza" post="vaccine. However, with a few exceptions [41,42,43], a great"/>
 <result pre="and could efficiently recognize HA proteins from heterologous group 1" exact="influenza" post="viruses; notably, cross-reactivity with group 2 antigens was also"/>
 <result pre="stalk-reactive antibodies afford little cross-protection between group 1 and 2" exact="influenza" post="viruses. Importantly, H3N2 viruses show the highest degree of"/>
 <result pre="highest degree of antigenic drift when compared to other seasonal" exact="influenza" post="viruses, posing the greatest risk of unmatched seasonal vaccine"/>
 <result pre="2 viruses to achieve a complete cross-protection against type A" exact="influenza" post="[22,23,24], here we bypass the issue of insufficient cross-protective"/>
 <result pre="have been shown to result in significant protection against divergent" exact="influenza" post="viruses, probably because the high level of IgG1 antibodies"/>
 <result pre="high-yield antigen production, an important hallmark for a broadly protective" exact="influenza" post="vaccine, accessible to the general public. Even though in"/>
 <result pre="virus-neutralizing antibody. Although some anti-stalk antibodies can directly neutralize the" exact="influenza" post="virus [41,42,43], antibodies against M2e do not possess virus-neutralizing"/>
 <result pre="Additional challenge experiment with a high dose of homologous H1N1" exact="influenza" post="virus emphasized the important role of tri-stalk targeted antibody"/>
 <result pre="responses and monitoring weight loss and survival upon a lethal" exact="influenza" post="virus challenge. Assessment of virus replication in the mouse"/>
 <result pre="particulate properties [63]. 5. Conclusions The combination of multiple conserved" exact="influenza" post="antigens into a multivalent single-component AP-M2e/tri-stalk vaccine protected mice"/>
 <result pre="multivalent single-component AP-M2e/tri-stalk vaccine protected mice from high dose homologous" exact="influenza" post="challenge and induced robust heterosubtypic immunity. Since persistent vaccine-induced"/>
 <result pre="immunity is a highly desirable feature of a broadly protective" exact="influenza" post="vaccine, it should be noted that both the post-fusion"/>
 <result pre="vaccine prototype might provide broad protection against seasonal and emergent" exact="influenza" post="strains, thus replacing the current vaccination strategies. Supplementary Materials"/>
 <result pre="acid sequences of N-terminally extended long alfa-helix fragment of various" exact="influenza" post="A HA proteins used in this study, Table S3:"/>
 <result pre="between the vaccination antigens and the corresponding protein fragments of" exact="influenza" post="A challenge viruses used in this study. LINK Click"/>
 <result pre="influenza-associated respiratory mortality: A modelling studyLancet20183911285130010.1016/S0140-6736(17)33293-229248255 3.PutriW.C.W.S.MuscatelloD.J.StockwellM.S.NewallA.T.Economic burden of seasonal" exact="influenza" post="in the United StatesVaccine2018363960396610.1016/j.vaccine.2018.05.05729801998 4.PreaudE.DurandL.MacabeoB.FarkasN.SloesenB.PalacheA.ShupoF.SamsonS.I.collab: Vaccines Europe Influenza Working"/>
 <result pre="Influenza Working GroupAnnual public health and economic benefits of seasonal" exact="influenza" post="vaccination: A European estimateBMC Public Health20141481310.1186/1471-2458-14-81325103091 5.collab: CDCCDC Seasonal"/>
 <result pre="ECDCInfluenza Vaccine EffectivenessAvailable online: https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccine-effectiveness(accessed on 6 March 2020) 7.BelongiaE.A.SimpsonM.D.KingJ.P.SundaramM.E.KelleyN.S.OsterholmM.T.McLeanH.Q.Variable" exact="influenza" post="vaccine effectiveness by subtype: A systematic review and meta-analysis"/>
 <result pre="design studiesLancet Infect. Dis.20161694295110.1016/S1473-3099(16)00129-827061888 8.BedfordT.RileyS.BarrI.G.BroorS.ChadhaM.CoxN.J.DanielsR.S.GunasekaranC.P.HurtA.C.KelsoA.et al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic driftNature201552321722010.1038/nature1446026053121 9.HeatonN.S.SachsD.ChenC.-J.HaiR.PaleseP.Genome-wide mutagenesis of influenza"/>
 <result pre="seasonal influenza viruses vary with antigenic driftNature201552321722010.1038/nature1446026053121 9.HeatonN.S.SachsD.ChenC.-J.HaiR.PaleseP.Genome-wide mutagenesis of" exact="influenza" post="virus reveals unique plasticity of the hemagglutinin and NS1"/>
 <result pre="hemagglutinin and NS1 proteinsProc. Natl. Acad. Sci. USA2013110202482025310.1073/pnas.132052411024277853 10.WongK.K.Y.RockmanS.OngC.BullR.Stelzer-BraidS.RawlinsonW.Comparison of" exact="influenza" post="virus replication fidelity in vitro using selection pressure with"/>
 <result pre="Memory Toward Unpredictable Influenza VirusesFront. Immunol.201910140010.3389/fimmu.2019.0140031312199 12.TscherneD.M.GarcÃ­a-SastreA.Virulence determinants of pandemic" exact="influenza" post="virusesJ. Clin. Investig.201112161310.1172/JCI4494721206092 13.LukszaM.LÃ¤ssigM.A predictive fitness model for influenzaNature2014507576110.1038/nature1308724572367"/>
 <result pre="13.LukszaM.LÃ¤ssigM.A predictive fitness model for influenzaNature2014507576110.1038/nature1308724572367 14.HannounC.The evolving history of" exact="influenza" post="viruses and influenza vaccinesExpert Rev. Vaccines2013121085109410.1586/14760584.2013.82470924024871 15.BazM.LukeC.J.ChengX.JinH.SubbaraoK.H5N1 vaccines in"/>
 <result pre="model for influenzaNature2014507576110.1038/nature1308724572367 14.HannounC.The evolving history of influenza viruses and" exact="influenza" post="vaccinesExpert Rev. Vaccines2013121085109410.1586/14760584.2013.82470924024871 15.BazM.LukeC.J.ChengX.JinH.SubbaraoK.H5N1 vaccines in humansVirus Res.2013178789810.1016/j.virusres.2013.05.00623726847 16.NuÃ±ezI.A.RossT.M.A"/>
 <result pre="Vaccines2013121085109410.1586/14760584.2013.82470924024871 15.BazM.LukeC.J.ChengX.JinH.SubbaraoK.H5N1 vaccines in humansVirus Res.2013178789810.1016/j.virusres.2013.05.00623726847 16.NuÃ±ezI.A.RossT.M.A review of H5Nx" exact="avian influenza" post="virusesTher. Adv. Vaccines Immunother.20197251513551882162510.1177/251513551882162530834359 17.WeiS.-H.YangJ.-R.WuH.-S.ChangM.-C.LinJ.-S.LinC.-Y.LiuY.-L.LoY.-C.YangC.-H.ChuangJ.-H.et al.Human infection with avian"/>
 <result pre="15.BazM.LukeC.J.ChengX.JinH.SubbaraoK.H5N1 vaccines in humansVirus Res.2013178789810.1016/j.virusres.2013.05.00623726847 16.NuÃ±ezI.A.RossT.M.A review of H5Nx avian" exact="influenza" post="virusesTher. Adv. Vaccines Immunother.20197251513551882162510.1177/251513551882162530834359 17.WeiS.-H.YangJ.-R.WuH.-S.ChangM.-C.LinJ.-S.LinC.-Y.LiuY.-L.LoY.-C.YangC.-H.ChuangJ.-H.et al.Human infection with avian"/>
 <result pre="avian influenza virusesTher. Adv. Vaccines Immunother.20197251513551882162510.1177/251513551882162530834359 17.WeiS.-H.YangJ.-R.WuH.-S.ChangM.-C.LinJ.-S.LinC.-Y.LiuY.-L.LoY.-C.YangC.-H.ChuangJ.-H.et al.Human infection with" exact="avian influenza" post="A H6N1 virus: An epidemiological analysisLancet Respir. Med.2013177177810.1016/S2213-2600(13)70221-224461756 18.GaoR.CaoB.HuY.FengZ.WangD.HuW.ChenJ.JieZ.QiuH.XuK.et"/>
 <result pre="influenza virusesTher. Adv. Vaccines Immunother.20197251513551882162510.1177/251513551882162530834359 17.WeiS.-H.YangJ.-R.WuH.-S.ChangM.-C.LinJ.-S.LinC.-Y.LiuY.-L.LoY.-C.YangC.-H.ChuangJ.-H.et al.Human infection with avian" exact="influenza" post="A H6N1 virus: An epidemiological analysisLancet Respir. Med.2013177177810.1016/S2213-2600(13)70221-224461756 18.GaoR.CaoB.HuY.FengZ.WangD.HuW.ChenJ.JieZ.QiuH.XuK.et"/>
 <result pre="analysisLancet Respir. Med.2013177177810.1016/S2213-2600(13)70221-224461756 18.GaoR.CaoB.HuY.FengZ.WangD.HuW.ChenJ.JieZ.QiuH.XuK.et al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virusN. Engl. J. Med.20133681888189710.1056/NEJMoa130445923577628 19.ChenH.YuanH.GaoR.ZhangJ.WangD.XiongY.FanG.YangF.LiX.ZhouJ.et al.Clinical and"/>
 <result pre="19.ChenH.YuanH.GaoR.ZhangJ.WangD.XiongY.FanG.YangF.LiX.ZhouJ.et al.Clinical and epidemiological characteristics of a fatal case of" exact="avian influenza" post="A H10N8 virus infection: A descriptive studyLancet201438371472110.1016/S0140-6736(14)60111-224507376 20.NachbagauerR.KrammerF.Universal influenza"/>
 <result pre="al.Clinical and epidemiological characteristics of a fatal case of avian" exact="influenza" post="A H10N8 virus infection: A descriptive studyLancet201438371472110.1016/S0140-6736(14)60111-224507376 20.NachbagauerR.KrammerF.Universal influenza"/>
 <result pre="avian influenza A H10N8 virus infection: A descriptive studyLancet201438371472110.1016/S0140-6736(14)60111-224507376 20.NachbagauerR.KrammerF.Universal" exact="influenza" post="virus vaccines and therapeutic antibodiesClin. Microbiol. Infect.20172322222810.1016/j.cmi.2017.02.00928216325 21.ValkenburgS.A.MallajosyulaV.V.A.LiO.T.W.ChinA.W.H.CarnellG.TempertonN.VaradarajanR.PoonL.L.M.Stalking influenza"/>
 <result pre="20.NachbagauerR.KrammerF.Universal influenza virus vaccines and therapeutic antibodiesClin. Microbiol. Infect.20172322222810.1016/j.cmi.2017.02.00928216325 21.ValkenburgS.A.MallajosyulaV.V.A.LiO.T.W.ChinA.W.H.CarnellG.TempertonN.VaradarajanR.PoonL.L.M.Stalking" exact="influenza" post="by vaccination with pre-fusion headless HA mini-stemSci. Rep.201662266610.1038/srep2266626947245 22.KrammerF.PicaN.HaiR.MargineI.PaleseP.Chimeric"/>
 <result pre="by vaccination with pre-fusion headless HA mini-stemSci. Rep.201662266610.1038/srep2266626947245 22.KrammerF.PicaN.HaiR.MargineI.PaleseP.Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodiesJ. Virol.2013876542655010.1128/JVI.00641-1323576508"/>
 <result pre="particle vaccine with adjuvant protects mice against homologous and heterologous" exact="influenza" post="virusesVaccine2016346464647110.1016/j.vaccine.2016.11.02627866773 24.ChenS.ZhengD.LiC.ZhangW.XuW.LiuX.FangF.ChenZ.Protection against multiple subtypes of influenza viruses by"/>
 <result pre="homologous and heterologous influenza virusesVaccine2016346464647110.1016/j.vaccine.2016.11.02627866773 24.ChenS.ZhengD.LiC.ZhangW.XuW.LiuX.FangF.ChenZ.Protection against multiple subtypes of" exact="influenza" post="viruses by virus-like particle vaccines based on a hemagglutinin"/>
 <result pre="vaccines based on a hemagglutinin conserved epitopeBioMed Res. Int.2015201590181710.1155/2015/90181725767809 25.KolpeA.SchepensB.FiersW.SaelensX.M2-based" exact="influenza" post="vaccines: Recent advances and clinical potentialExpert Rev. Vaccines20171612313610.1080/14760584.2017.124004127653543 26.De"/>
 <result pre="Recent advances and clinical potentialExpert Rev. Vaccines20171612313610.1080/14760584.2017.124004127653543 26.De FiletteM.Min JouW.BirkettA.LyonsK.SchultzB.TonkyroA.ReschS.FiersW.Universal" exact="influenza" post="A vaccine: Optimization of M2-based constructsVirology200533714916110.1016/j.virol.2005.04.00415914228 27.SuiZ.ChenQ.WuR.ZhangH.ZhengM.WangH.ChenZ.Cross-protection against influenza"/>
 <result pre="JouW.BirkettA.LyonsK.SchultzB.TonkyroA.ReschS.FiersW.Universal influenza A vaccine: Optimization of M2-based constructsVirology200533714916110.1016/j.virol.2005.04.00415914228 27.SuiZ.ChenQ.WuR.ZhangH.ZhengM.WangH.ChenZ.Cross-protection against" exact="influenza" post="virus infection by intranasal administration of M2-based vaccine with"/>
 <result pre="induces humoral and cellular immune responses conferring cross-protection against heterosubtypic" exact="influenza" post="virusesPLoS ONE201813e019086810.1371/journal.pone.019086829324805 29.RamirezA.MorrisS.MaucourantS.Dâ€™AscanioI.CrescenteV.LuI.-N.FarinelleS.MullerC.P.WhelanM.RosenbergW.A virus-like particle vaccine candidate for influenza"/>
 <result pre="heterosubtypic influenza virusesPLoS ONE201813e019086810.1371/journal.pone.019086829324805 29.RamirezA.MorrisS.MaucourantS.Dâ€™AscanioI.CrescenteV.LuI.-N.FarinelleS.MullerC.P.WhelanM.RosenbergW.A virus-like particle vaccine candidate for" exact="influenza" post="A virus based on multiple conserved antigens presented on"/>
 <result pre="influenza A virus based on multiple conserved antigens presented on" exact="hepatitis" post="B tandem core particlesVaccine20183687388010.1016/j.vaccine.2017.12.05329306508 30.EllebedyA.H.AhmedR.Re-engaging cross-reactive memory B cells:"/>
 <result pre="B tandem core particlesVaccine20183687388010.1016/j.vaccine.2017.12.05329306508 30.EllebedyA.H.AhmedR.Re-engaging cross-reactive memory B cells: The" exact="influenza" post="puzzleFront. Immunol.201235310.3389/fimmu.2012.0005322566934 31.PushkoP.PumpensP.GrensE.Development of virus-like particle technology from small"/>
 <result pre="ObanosM.P.KrimerA.et al.Production and purification of chimeric HBc virus-like particles carrying" exact="influenza" post="virus LAH domain as vaccine candidatesBMC Biotechnol.2017177910.1186/s12896-017-0396-829126399 34.AdachiY.TonouchiK.NithichanonA.KuraokaM.WatanabeA.ShinnakasuR.AsanumaH.AinaiA.OhmiY.YamamotoT.et al.Exposure"/>
 <result pre="occluded hemagglutinin epitope drives selection of a class of cross-protective" exact="influenza" post="antibodiesNat. Commun.201910388310.1038/s41467-019-11821-631462639 35.LuI.-N.KirsteinaA.FarinelleS.WilliemeS.TarsK.MullerC.P.KazaksA.Structure and applications of novel influenza HA"/>
 <result pre="of cross-protective influenza antibodiesNat. Commun.201910388310.1038/s41467-019-11821-631462639 35.LuI.-N.KirsteinaA.FarinelleS.WilliemeS.TarsK.MullerC.P.KazaksA.Structure and applications of novel" exact="influenza" post="HA tri-stalk protein for evaluation of HA stem-specific immunityPLoS"/>
 <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccinationImmunology201414330030910.1111/imm.1231024773389 37.LeserG.P.LambR.A.Influenza virus assembly and budding in raft-derived"/>
 <result pre="39.JegaskandaS.WeinfurterJ.T.FriedrichT.C.KentS.J.Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1" exact="influenza" post="virus infection of macaquesJ. Virol.2013875512552210.1128/JVI.03030-1223468501 40.KrystalM.ElliottR.M.BenzE.W.YoungJ.F.PaleseP.Evolution of influenza A"/>
 <result pre="pandemic H1N1 influenza virus infection of macaquesJ. Virol.2013875512552210.1128/JVI.03030-1223468501 40.KrystalM.ElliottR.M.BenzE.W.YoungJ.F.PaleseP.Evolution of" exact="influenza" post="A and B viruses: Conservation of structural features in"/>
 <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutininsScience201133385085610.1126/science.120566921798894 42.NakamuraG.ChaiN.ParkS.ChiangN.LinZ.ChiuH.FongR.YanD.KimJ.ZhangJ.et al.An in vivo human-plasmablast enrichment technique"/>
 <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodiesCell Host Microbe2013149310310.1016/j.chom.2013.06.00423870317 43.DreyfusC.LaursenN.S.KwaksT.ZuijdgeestD.KhayatR.EkiertD.C.LeeJ.H.MetlagelZ.BujnyM.V.JongeneelenM.et al.Highly conserved protective epitopes"/>
 <result pre="A antibodiesCell Host Microbe2013149310310.1016/j.chom.2013.06.00423870317 43.DreyfusC.LaursenN.S.KwaksT.ZuijdgeestD.KhayatR.EkiertD.C.LeeJ.H.MetlagelZ.BujnyM.V.JongeneelenM.et al.Highly conserved protective epitopes on" exact="influenza" post="B virusesScience20123371343134810.1126/science.122290822878502 44.ThrosbyM.van den BrinkE.JongeneelenM.PoonL.L.M.AlardP.CornelissenL.BakkerA.CoxF.van DeventerE.GuanY.et al.Heterosubtypic neutralizing monoclonal"/>
 <result pre="Microbe20161980081310.1016/j.chom.2016.05.01427281570 47.EkiertD.C.FriesenR.H.E.BhabhaG.KwaksT.JongeneelenM.YuW.OphorstC.CoxF.KorseH.J.W.M.BrandenburgB.et al.A highly conserved neutralizing epitope on group 2" exact="influenza" post="A virusesScience201133384385010.1126/science.120483921737702 48.DiLilloD.J.TanG.S.PaleseP.RavetchJ.V.Broadly neutralizing hemagglutinin stalk-specific antibodies require FcÎ³R"/>
 <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcÎ³R interactions for protection against" exact="influenza" post="virus in vivoNat. Med.20142014315110.1038/nm.344324412922 49.NimmerjahnF.RavetchJ.V.Divergent immunoglobulin g subclass activity"/>
 <result pre="receptors: Old friends and new family membersImmunity200624192810.1016/j.immuni.2005.11.01016413920 51.SchmitzN.BeerliR.R.BauerM.JegerlehnerA.DietmeierK.MaudrichM.PumpensP.SaudanP.BachmannM.F.Universal vaccine against" exact="influenza" post="virus: Linking TLR signaling to anti-viral protectionEur. J. Immunol.20124286386910.1002/eji.20104122522531913"/>
 <result pre="signaling to anti-viral protectionEur. J. Immunol.20124286386910.1002/eji.20104122522531913 52.StepanovaL.A.KotlyarovR.Y.KovalevaA.A.PotapchukM.V.KorotkovA.V.SergeevaM.V.KasianenkoM.A.KuprianovV.V.RavinN.V.TsybalovaL.M.et al.Protection against multiple" exact="influenza" post="A virus strains induced by candidate recombinant vaccine based"/>
 <result pre="bacteriophage-like particles for the packaging of nanomaterialsMol. Biotechnol.20145610211010.1007/s12033-013-9686-023852987 55.MezhenskayaD.Isakova-SivakI.RudenkoL.M2e-based universal" exact="influenza" post="vaccines: A historical overview and new approaches to developmentJ."/>
 <result pre="BakkouriK.YsenbaertT.DengL.et al.M2e-tetramer-specific memory CD4 T cells are broadly protective against" exact="influenza" post="infectionMucosal Immunol.20181127328910.1038/mi.2017.1428295019 58.BrownD.M.DilzerA.M.MeentsD.L.SwainS.L.CD4 T cell-mediated protection from lethal influenza:"/>
 <result pre="Perforin and antibody-mediated mechanisms give a one-two punchJ. Immunol.20061772888289810.4049/jimmunol.177.5.288816920924 59.SchotsaertM.IbaÃ±ezL.I.FiersW.SaelensX.Controlling" exact="influenza" post="by cytotoxic T-cells: Calling for help from destroyersJ. Biomed."/>
 <result pre="viruses on immunogenicity and protection induced by a candidate universal" exact="influenza" post="vaccine in micePLoS ONE201914e021532110.1371/journal.pone.021532130986224 61.Herrera-RodriguezJ.MeijerhofT.NiestersH.G.StjernholmG.HovdenA.-O.SÃ¸rensenB.Ã–kvistM.SommerfeltM.A.HuckriedeA.A novel peptide-based vaccine candidate"/>
 <result pre="ONE201914e021532110.1371/journal.pone.021532130986224 61.Herrera-RodriguezJ.MeijerhofT.NiestersH.G.StjernholmG.HovdenA.-O.SÃ¸rensenB.Ã–kvistM.SommerfeltM.A.HuckriedeA.A novel peptide-based vaccine candidate with protective efficacy against" exact="influenza" post="A in a mouse modelVirology2018515212810.1016/j.virol.2017.11.01829223787 62.Asthagiri ArunkumarG.McMahonM.PavotV.AramouniM.IoannouA.LambeT.GilbertS.KrammerF.Vaccination with viral"/>
 <result pre="expressing NP, M1 and chimeric hemagglutinin induces broad protection against" exact="influenza" post="virus challenge in miceVaccine2019375567557710.1016/j.vaccine.2019.07.09531399277 63.KangS.-M.KimM.-C.CompansR.W.Virus-like particles as universal influenza"/>
 <result pre="against influenza virus challenge in miceVaccine2019375567557710.1016/j.vaccine.2019.07.09531399277 63.KangS.-M.KimM.-C.CompansR.W.Virus-like particles as universal" exact="influenza" post="vaccinesExpert Rev. Vaccines201211995100710.1586/erv.12.7023002980 64.SchwartzmanL.M.CathcartA.L.PujanauskiL.M.QiL.KashJ.C.TaubenbergerJ.K.An Intranasal Virus-Like Particle Vaccine Broadly"/>
 <result pre="0.0001). Figure 9 Immune protection conferred against lethal H1N1 A/California/7/2009" exact="influenza" post="virus challenge. (A) BALB/c mice were vaccinated with Alum-adjuvanted"/>
</results>
